Up to 192 transfection experiments can be performed in parallel.
UK-based scientific medical research devices company nanoTherics, has introduced the magnefect-nano II DUO and the magnefect-LT DUO transfection systems which enable up to 192 transfection experiments to be performed in parallel.
These new, compact devices offer gene transfection with improved efficiencies and cell viabilities, even with a range of difficult cell types including neuronal and primary cells.
They use a unique technology which applies oscillating magnet arrays to promote magnetic nanoparticle/DNA uptake into cells to improve non-viral gene transfection, whilst maintaining high cell viability.
They are simple to use with low running costs (as low as $0.1 per transfection) providing improved transfection efficiency and effectiveness over the best currently available cationic lipids at short transfection times (<30 minutes).
They allow retransfection as well as adherent state transfection for user flexibility.
The magnefect-nano II DUO provides full flexibility with interchangeable 2x6, 24 and 96-well magnet array formats and variable oscillating frequency capability to enable researchers to optimise protocols to maximise transfections specifically for the cell types they are using.
The magnefect-LT DUO is a lower cost system with fixed oscillating frequency and fixed 2x6-well or 2x24-well or 2x96-well magnet array formats.
The primary focus of nanoTherics, which was founded in 2007 following on from biomedical research conducted at Keele University and the University of Florida, is supply of scientific devices and associated products to research labs in the pharmaceutical and biotechnology industries and academia.
Sales are showing a strong market interest in the patented oscillating magnetic field technology from nanoTherics which improves delivery of important molecules, such as DNA, into living cells.
The medium to long-term opportunity for this approach relates to more effective non-viral gene therapy, an area demanding safer technology to treat genetic diseases and disorders including cancers, Parkinson's disease, multiple sclerosis and cystic fibrosis.
For more information on nanoTherics please visit the company website on www.nanotherics.com.
If you would like further information on the attached press release please do not hesitate to contact me at linda@nanotherics.com.
